What this is
- How it works
- How it works isn't classified yet
- Main trialPhase 1
- “The purpose of this study is to determine the safety and tolerability of XmAb657 in healthy participants and participants with autoimmune diseases. Participants will be given XmAb657 subcutaneously (SC) by injection under the skin.”In the company’s words, NCT07284797 on ClinicalTrials.gov
Other drugs for Idiopathic Inflammatory Myopathies
- AnifrolumabAstraZeneca · Phase 3
- CABA-201Cabaletta Bio · Phase 2/3
- Efgartigimodargenx · Phase 3
- ULSCRestem, LLC. · Phase 2/3
- UlviprubartAbcuro, Inc. · Phase 2/3
- AndecaliximabAshibio Inc · Phase 2/3
Coming up1
- Oct 2028Phase 1 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Recruiting | Oct 2028 | A Phase 1 Open-label Study to Evaluate Safety in Healthy Participants and Participants With Autoimmune Diseases |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026